Clinical trial
A Phase 2, Three-arm, Randomized Study of the Efficacy of Intratumorally Administered L19IL2 or L19TNF or L19IL2/L19TNF, All in Combination With Systemic Anti-PD1 Pembrolizumab, in Stage III and IV Unresectable Melanoma Patients With Resistance to or Progressing Upon Anti-PD1 Checkpoint Inhibitors and With Presence of Injectable Metastases
NCT06284590 is registered in ClinicalTrials.gov with Philogen S.p.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Three-arm, Randomized Study of the Efficacy of Intratumorally Administered L19IL2 or L19TNF or L19IL2/L19TNF, All in Combination With Systemic Anti-PD1 Pembrolizumab, in Stage III and IV Unresectable Melanoma Patients With Resistance to or Progressing Upon Anti-PD1 Checkpoint Inhibitors and With Presence of Injectable Metastases
- Lead sponsor
- Philogen S.p.A.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- July 12, 2024
- Completion date
- July 31, 2028
- Enrollment
- 162 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
melanoma stage iii, melanoma stage iv